Étiquette : suicide

Bibliographie : Kétamine, Dr Christian Sueur, GRECC, novembre 2019

Bibliographie : Kétamine Dr Christian Sueur, GRECC, novembre 2019   Kétamine en Psychiatrie .......................................................1 Kétamine et psychose ...........................................................2 Kétamine et traitement de la dépression ..............................3 Kétamine et prise en charge de l'idéation suicidaire ...........11 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) ......12 Kétamine et addictions .........................................................13 Kétamine et sevrage des opiacés ..........................................14 Kétamine et prise en charge de la douleur ...........................15 Kétamine et prise en charge de la douleur chez l'enfant .....16 Pharmacologie de la kétamine ..............................................17 Neurophysiologie de la kétamine .........................................18 Neurotoxicologie de la kétamine ..........................................20 Kétamine et effets indésirables .............................................20  

Lire la suite

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial, Richard J. Zeifman et al., 2019

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325   Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]

Lire la suite

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women, Elena Argento et al., 2018

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women Elena Argento, Melissa Braschel, Zach Walsh, M. Eugenia Socias and Kate Shannon Journal of Psychopharmacology, 2018, 1–7 DOI : 10.1177/0269881118798610   Abstract Background/aims : Given high rates of depression and suicide among marginalized women, and increasing calls to integrate trauma-informed biomedical and community-led structural interventions, this study longitudinally examines the potential moderating effect of psychedelic use on the relationship between other illicit drug use and suicide risk. Methods : Data (2010–2017) were drawn from a community-based, prospective open cohort of marginalized women in Vancouver, Canada. Extended Cox regression [...]

Lire la suite

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences, Theresa M. Carbonaro et al., 2016

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]

Lire la suite

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study, Carla M. Canuso et al., 2018,

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Carla M. Canuso, M.D., Jaskaran B. Singh, M.D., Maggie Fedgchin, Pharm.D., Larry Alphs, M.D., Ph.D., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Pinter, M.S., David Hough, M.D., Gerard Sanacora, M.D., Ph.D., Husseini Manji, M.D., Wayne C. Drevets, M.D. American Journal of Psychiatry, 2018, 175, 620–630 doi: 10.1176/appi.ajp.2018.17060720   Objective : The authors compared the efficacy of standardof- care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among [...]

Lire la suite

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, P.S. Hendricks et al., 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population Peter S Hendricks, Christopher B Thorne, C Brendan Clark, David W Coombs, and Matthew W Johnson Journal of Psychopharmacology · January 2015 DOI: 10.1177/0269881114565653 ·   Abstract : Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA [...]

Lire la suite